Standard treatment for type 2 diabetes has been to use oral therapy until the disease progresses, but researchers are rethinking that approach.
A pilot study involving patients with type 2 diabetes (T2D) showed that early insulin therapy had the same benefit as 15 months’ worth of oral therapy and may help increase the body’s ability to produce insulin on its own.
It’s the latest study to show the benefits of early, intense treatment for patients with T2D as a way of forestalling disease progression, more akin to the way cancer is treated. Historically, T2D has been handled with a treat-to-failure approach, in which patients are given the least intense therapy first, followed by medications of increasing intensity as the disease worsens.
In this small study of 23 subjects, conducted by Ohio University and Wester University of Health Sciences College of Osteopathic Medicine, the group given insulin showed significantly reduced levels of glycated hemoglobin (A1C), from 10.1% to 6.7%, after 15 months. The oral therapy group had its A1C drop from 9.9% to 6.8%..
The insulin group saw other benefits, however. It did not experience severe hypoglycemia and lost 5 pounds on average, while the oral therapy group gained weight.
Researchers said the study showed that insulin therapy preserves the pancreas’ ability to respond to glucose and produce insulin. They called for an expansion of the study.
“While the improvement in glucose was relatively comparable between the 2 groups, our findings support the idea that the body can improve its natural insulin secreting ability when early insulin is given,” said lead author Jay Shubrook, DO. “This may be because early insulin therapy protects beta cells in the pancreas that response to glucose and produce insulin.”
The study was reported this week by the American Osteopathic Association.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen